Tags : tisagenlecleucel


Novartis’ Kymriah (tisagenlecleucel) Receives the US FDA’s Regenerative Medicine Advanced

Shots: Shots: The US FDA has granted RMAT designation to Novartis’ Kymriah (tisagenlecleucel) to treat patients with r/r FL. The designation is based on P-II ELARA study evaluating the efficacy and safety of tisagenlecleucel in adult patients with r/r FL The RMAT designation supports the advancement of Kymriah and reflects the unmet need for patients […]Read More